Author Bio
Sushree is a new member of the Fool family, keen on writing about the cannabis and healthcare sector and also has five years of experience writing on real estate, consumer sector, and macroeconomic topics. She holds a bachelor’s degree in business management, specializing in finance, and also a CFA Level 2 candidate. Being a fitness enthusiast and a creative person, when she isn t writing, she is either kick-boxing or painting.
Canopy Growth (NASDAQ:CGC) has always been an investor favorite, even though it s struggled from time to time. After a 2019 in which the cannabis industry suffered some major setbacks, Canopy tried its best to get back on track in 2020. Even though it wasn t enough to bring in profits, the company finally saw its revenue rising.
Tilray (NASDAQ:TLRY) made headlines in December when they announced they would be joining forces. Mega-mergers like this aren t common in the cannabis industry, especially not ones that fuse a pair of its bigger players.
But investors aren t too excited about this deal Aphria s stock price has slid in the weeks since the announcement, from more than $8 a share to under $7. The Ontario-based pot stock is still up around 35% year to date, however, wildly outperforming the
Horizons Marijuana Life Sciences ETF, which is down 3%.
Has this month s slide opened up an opportunity to buy Aphria shares at a discount, or will the merger with Tilray drag the stock even further down?
Author Bio
Sushree is a new member of the Fool family, keen on writing about the cannabis and healthcare sector and also has five years of experience writing on real estate, consumer sector, and macroeconomic topics. She holds a bachelor’s degree in business management, specializing in finance, and also a CFA Level 2 candidate. Being a fitness enthusiast and a creative person, when she isn t writing, she is either kick-boxing or painting.
When investors talk about cannabis stocks, Canadian players
Canopy Growth (NASDAQ:CGC) come to mind. But in 2020, U.S. cannabis companies not only proved their potential, but outperformed their Canadian counterparts. Two such companies are Illinois-based
Author Bio
Sushree is a new member of the Fool family, keen on writing about the cannabis and healthcare sector and also has five years of experience writing on real estate, consumer sector, and macroeconomic topics. She holds a bachelor’s degree in business management, specializing in finance, and also a CFA Level 2 candidate. Being a fitness enthusiast and a creative person, when she isn t writing, she is either kick-boxing or painting.
U.S. cannabis stocks often get overlooked in favor of popular Canadian players like
Aurora Cannabis and
Canopy Growth. But if you look at their revenue growth even in a limited legal market, you will understand why U.S. stocks are actually the better options. While marijuana is still illegal at a federal level in the U.S., more states made cannabis legal in the November 2020 elections, presenting more opportunities for expansion. Currently, 35 states and the District of Colombia allow the medical use of cannabis, wh
Author Bio
Sushree is a new member of the Fool family, keen on writing about the cannabis and healthcare sector and also has five years of experience writing on real estate, consumer sector, and macroeconomic topics. She holds a bachelor’s degree in business management, specializing in finance, and also a CFA Level 2 candidate. Being a fitness enthusiast and a creative person, when she isn t writing, she is either kick-boxing or painting.
While many Canadian pot stocks have struggled in 2020, a few U.S. cannabis stocks had a marvelous year among them,
Curaleaf Holdings (OTC:CURLF). While the benchmark